Osteoporosis Drug Could Raise the Treatment Bar
In the ARCH trial, romosozumab plus alendronate outperformed alendronate alone in reducing fracture risk.
4 New Things About Osteoporosis
The latest research findings reveal new aspects of diagnosis, treatment, and prevention.
Osteoporosis Drug Costs Called Into Question
An ICER analysis and expert commentary on anabolics’ benefits and costs offer some opposing views, and some consensus.
Osteoporosis Pharmacotherapy Use Falls Short
Only a minority of postmenopausal women reported using appropriate therapy other than estrogen to reduce future fractures.
Romosozumab Continues to Build Bone, Reduce Fracture Risk
EULAR 2017: Romosozumab reduces the risk of clinical vertebral fractures in postmenopausal women with osteoporosis by as much as five times.
15 Recommendations for Treating Glucocorticoid-Induced Osteoporosis
For the first time in seven years, the ACR has new treatment recommendations for glucocorticoid-induced osteoporosis. In this slideshow, we highlight the new guidelines.
Drug Roundup: New FDA-Approved Treatments in Rheumatology
In this slideshow, we offer a glance at newly approved treatments for rheumatoid arthritis, juvenile arthritis, osteoporosis and fingernail psoriasis, among other conditions.
Diagnosis Checklist: Osteoporosis
Women with osteoporosis may not know they have osteoporosis until their first fracture. In this slideshow, we outline a few reminders for physicians when evaluating patients for osteoporosis.
Six Risk Factors for Low Bone Mineral Density in Lupus
Low bone mineral density and osteoporosis are well-known comorbidities with systemic lupus erythematosus. In this slideshow, we highlight six of the most common risk factors for low bone mineral density in SLE.
By clicking Accept, you agree to become a member of the UBM Medica Community.